Clinical trialNCT01319981CompletedPhase 2Interventional

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

SponsorM.D. Anderson Cancer CenterEnrollment31Leukemia

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Elias Jabbour, MD
M.D. Anderson Cancer Center
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Texas Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cytarabine →Cyclophosphamide →Dexamethasone →Doxorubicin →G-CSF →Imatinib →Mesna →Methotrexate →Pegfilgrastim →Rituximab →Methylprednisolone →VSLI

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Mar 2013
Primary completion: 11 Nov 2020
Completion: 11 Nov 2020
Last update posted: 27 Sept 2022
Registered enrollment: 31
Registry id: NCT01319981

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.